KYMR

115.3103.42%
PE

Pamela Esposito

Independent Director

Dr. Pamela Esposito, Ph.D, is Director of Sapience Therapeutics, Inc. from December 2024. She joined Sapience Therapeutics, Inc. in December 2024. She is Advisor at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). She had been Chief Business Officer at Replimune Group, Inc. (formerly known as Replimune Limited) since 2015 until April 01, 2024. Dr. Esposito serves as a Director of Accent Therapeutics Inc. She served as the Chief Business Officer at Ra Pharmaceuticals, Inc. from 2013 to 2015. Dr. Esposito serves as an Independent Director of Kymera Therapeutics, Inc. since September 4, 2020. Dr. Esposito served as Senior Vice President of Strategic Planning & Business Development at Angiochem Inc. Dr. Esposito joined Angiochem from BioVex Group, Inc. where she served as Vice President of Business Development from 2010 to 2011. At Biovex, she was responsible for the successful acquisition of Biovex by Amgen in 2011. She served as Director of Business Development and Commercialization at Vion Pharmaceuticals with responsibility for all business development activities. She was one of the first employees at a number of successful early stage companies, including Galenea and Bioduro, where she held a variety of strategic planning, business development and commercial positions with increasing responsibilities. Dr. Esposito earned a Ph.D. in Pharmacology from Tufts University School of Medicine in 2002 where her research focused on the physiologic regulation of the blood-brain-barrier and the implications on drug distribution and a B.A. in Biochemistry/Molecular Biology from Dartmouth College.

Positions